Lv5
1516 积分 2025-02-28 加入
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
2天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
3天前
已关闭
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
6天前
已完结
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
16天前
已完结
KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy
17天前
已完结
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
19天前
已完结
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial
26天前
已完结
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial
26天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
27天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
1个月前
已完结
皖公网安备34019202002308
